Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 7/20 | 0.47 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711503 | 0.84 | HPRT1 (0.37) | HPRT1NOS1 | |
| SCHEMBL712026 | 0.82 | HPRT1 (0.50) | HPRT1NOS1 | |
| Hydrochloric Acid SCHEMBL10507812 | 0.78 | HPRT1 (0.59) | HPRT1CYP3A4SMN1; SMN2NOS1 | |
| SCHEMBL417578 | 0.77 | HPRT1 (0.60) | HPRT1CYP3A4SMN1; SMN2NOS1 | |
| SCHEMBL709475 | 0.77 | HPRT1 (0.51) | HPRT1CYP3A4SMN1; SMN2 | |
| SCHEMBL711855 | 0.76 | PNP (0.47) | — | |
| SCHEMBL7745028 | 0.76 | HPRT1 (0.64) | HPRT1NOS1 | |
| Phosphoric Acid SCHEMBL571369 | 0.74 | HPRT1 (0.64) | HPRT1NOS1 | |
| SCHEMBL5509444 | 0.73 | HPRT1 (0.58) | HPRT1CYP3A4SMN1; SMN2NOS1 | |
| SCHEMBL710910 | 0.72 | HPRT1 (0.49) | HPRT1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8124609-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7432274-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2008-10-07 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| US-20040132749-A1 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-07-08 | — | — | US | disclosed |
| US-6703394-B2 | VIRICIDES SUCH AS (R)-9-(2-(STEAROYLOXYMETHYL)-4-(L-VALYLOXY) BUTYL)GUANINE FOR TREATMENT OF HIV; BIOAVAILABILITY | MEDIVIR AB (SE) | 2004-03-09 | — | — | US | disclosed |
| EP-0880521-B1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020188125-A1 | Acyclic nucleoside derivatives | MEDIVIR AB | 2002-12-12 | — | — | US | disclosed |
| US-6255312-B1 | VIRICIDES | MEDIVIR AB (SE) | 2001-07-03 | — | — | US | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| EP-0971923-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0888348-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 1999-01-07 | — | — | EP | disclosed |
| EP-0880521-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | Medivir Aktiebolag (SE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998034917-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1998-08-13 | — | — | WO | disclosed |
| WO-1997030051-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997030052-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | HPRT1 19/4885SMYD2 2613/4885CYP3A4 1612/4885 |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | HPRT1 16/4885SMYD2 2614/4885CYP3A4 1608/4885 |
| US-20040132749-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | HPRT1 25/4885SMYD2 2310/4885CYP3A4 2161/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | HPRT1 33/4885SMYD2 1850/4885CYP3A4 2519/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | HPRT1 32/4885SMYD2 2144/4885CYP3A4 1513/4885 |
| US-20020188125-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | HPRT1 20/4885SMYD2 1948/4885CYP3A4 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.